Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 16 Myeloid 8 Dermatologic 2 Classical hematology 2 Thoracic 1 Sarcoma 1 NET 1 Head & Neck 1 Genitourinary 1 Endocrine 1 CNS 1 Breast 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 36 Everolimus 32 pembrolizumab 24 Temozolomide 21 Magnetic Resonance Spectroscopy 21 Nivolumab 18 lenvatinib 17 gallium Ga 68 dotatate 16 cabozantinib 15 Cisplatin 15 lanreotide 14 3-Iodobenzylguanidine 14 Capecitabine 13 trametinib 12 dabrafenib 12 Bevacizumab 12 Octreotide 11 Surveys and Questionnaires 10 Surgical Procedures, Operative 10 Sunitinib 10 Radiosurgery 10 Positron Emission Tomography Computed Tomography 10 Blood Specimen Collection 10 Sorafenib 9 Paclitaxel 9 Ipilimumab 9 Carboplatin 9 surufatinib 8 Etoposide 8 Doxorubicin 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × decitabine and cedazuridine drug combination × Endocrine × Clear all

NCT05178693 2025-11-24

LANTana

Imperial College London

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡